WAVE Life Sciences Ltd.
WVE
$8.85
$0.222.55%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.70M | 9.18M | 83.75M | -7.68M | 19.69M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.70M | 9.18M | 83.75M | -7.68M | 19.69M |
| Cost of Revenue | 43.47M | 40.62M | 44.65M | 41.20M | 40.39M |
| Gross Profit | -34.77M | -31.45M | 39.10M | -48.87M | -20.70M |
| SG&A Expenses | 17.99M | 18.36M | 16.14M | 15.04M | 14.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 61.46M | 58.98M | 60.78M | 56.24M | 54.69M |
| Operating Income | -52.76M | -49.80M | 22.97M | -63.92M | -35.00M |
| Income Before Tax | -50.47M | -46.88M | 29.25M | -61.78M | -32.92M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -50.47M | -46.88M | 29.25M | -61.78M | -32.92M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.47M | -46.88M | 29.25M | -61.78M | -32.92M |
| EBIT | -52.76M | -49.80M | 22.97M | -63.92M | -35.00M |
| EBITDA | -51.89M | -48.93M | 23.87M | -62.97M | -34.00M |
| EPS Basic | -0.31 | -0.29 | 0.18 | -0.47 | -0.25 |
| Normalized Basic EPS | -0.19 | -0.18 | 0.11 | -0.29 | -0.16 |
| EPS Diluted | -0.31 | -0.29 | 0.17 | -0.47 | -0.25 |
| Normalized Diluted EPS | -0.19 | -0.18 | 0.11 | -0.29 | -0.16 |
| Average Basic Shares Outstanding | 163.99M | 162.53M | 161.49M | 132.56M | 129.53M |
| Average Diluted Shares Outstanding | 163.99M | 162.53M | 172.29M | 132.56M | 129.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |